Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cabozantinib prevents the progression of metabolic dysfunction-associated steatohepatitis by inhibiting the activation of hepatic stellate cell and macrophage and attenuating angiogenic activity.
Matsuda T, Kaji K, Nishimura N, Asada S, Koizumi A, Tanaka M, Yorioka N, Tsuji Y, Kitagawa K, Sato S, Namisaki T, Akahane T, Yoshiji H. Matsuda T, et al. Among authors: akahane t. Heliyon. 2024 Sep 27;10(19):e38647. doi: 10.1016/j.heliyon.2024.e38647. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39398008 Free PMC article.
All-in-one bimodal DNA and RNA next-generation sequencing panel for integrative diagnosis of glioma.
Higa N, Akahane T, Kirishima M, Yonezawa H, Makino R, Uchida H, Yokoyama S, Takajo T, Otsuji R, Fujioka Y, Sangatsuda Y, Kuga D, Yamahata H, Hata N, Horie N, Kurosaki M, Yamamoto J, Yoshimoto K, Tanimoto A, Hanaya R. Higa N, et al. Among authors: akahane t. Pathol Res Pract. 2024 Sep 28;263:155598. doi: 10.1016/j.prp.2024.155598. Online ahead of print. Pathol Res Pract. 2024. PMID: 39357189 Free article.
Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection who had received direct-acting antiviral therapy.
Tada T, Kurosaki M, Toyoda H, Tamaki N, Yasui Y, Nakamura S, Mori N, Tsuji K, Ochi H, Akahane T, Kobashi H, Fujii H, Marusawa H, Kondo M, Urawa N, Yoshida H, Uchida Y, Morita A, Hasebe C, Mitsuda A, Ogawa C, Narita R, Kubotsu Y, Matsushita T, Shigeno M, Okamoto E, Okada K, Kasai T, Ishii T, Nonogi M, Yasuda S, Koshiyama Y, Kumada T, Izumi N. Tada T, et al. Among authors: akahane t. Liver Int. 2024 Nov;44(11):3060-3071. doi: 10.1111/liv.16093. Epub 2024 Sep 2. Liver Int. 2024. PMID: 39223936
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma.
Mori N, Tamaki N, Takaki S, Tsuji K, Tada T, Nakamura S, Ochi H, Mashiba T, Doisaki M, Marusawa H, Kobashi H, Fujii H, Ogawa C, Nonogi M, Arai H, Uchida Y, Urawa N, Narita R, Akahane T, Kondo M, Yasui Y, Tsuchiya K, Izumi N, Kurosaki M. Mori N, et al. Among authors: akahane t. Invest New Drugs. 2024 Aug 30. doi: 10.1007/s10637-024-01470-y. Online ahead of print. Invest New Drugs. 2024. PMID: 39212893
Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma.
Tamaki N, Mori N, Takaki S, Tsuji K, Tada T, Nakamura S, Ochi H, Mashiba T, Doisaki M, Marusawa H, Kobashi H, Fujii H, Ogawa C, Nonogi M, Arai H, Uchida Y, Urawa N, Narita R, Akahane T, Kondo M, Yasui Y, Tsuchiya K, Izumi N, Kurosaki M. Tamaki N, et al. Among authors: akahane t. Anticancer Res. 2024 Sep;44(9):3913-3918. doi: 10.21873/anticanres.17219. Anticancer Res. 2024. PMID: 39197893
325 results